Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults | Zendy

Ira Gantz | Zendy; Ngozi Erondu | Zendy; Madhuja Mallick | Zendy; Bret J. Musser | Zendy; Rajesh Krishna | Zendy; Wesley Tanaka | Zendy; Karen Snyder | Zendy; Cathy Stevens | Zendy; Mark Stroh | Zendy; Haiyuan Zhu | Zendy; John A. Wagner | Zendy; Douglas J. MacNeil | Zendy; Steven B. Heymsfield | Zendy; John M. Amatruda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults

Author(s) -

Ira Gantz,

Ngozi Erondu,

Madhuja Mallick,

Bret J. Musser,

Rajesh Krishna,

Wesley Tanaka,

Karen Snyder,

Cathy Stevens,

Mark Stroh,

Haiyuan Zhu,

John A. Wagner,

Douglas J. MacNeil,

Steven B. Heymsfield,

John M. Amatruda

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-1806

Subject(s) - placebo , tolerability , medicine , postprandial , body mass index , context (archaeology) , weight loss , randomized controlled trial , nausea , endocrinology , obesity , gastroenterology , adverse effect , insulin , biology , alternative medicine , pathology , paleontology

The gastrointestinal peptide hormone, peptide YY(3-36) (PYY(3-36)), is implicated to be a postprandial satiety factor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research